Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga· 3 days agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Hearing set to consider penalties for pharmaceutical company over Arkansas law | Arkansas Democrat...
Arkansas Democrat-Gazette· 6 hours agoA battle between the Arkansas Insurance Department and pharmaceutical manufacturers is heating up...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 4 days agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck KGaA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 6 days agoMerck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29. As investors...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 6 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 6 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report released on Friday, Benzinga reports ...
Here's Why Merck (MRK) is a Strong Momentum Stock
Zacks· 2 days agoFor new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily ...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 3 days agoLast year, major pharmaceutical companies heavily invested in R&D, with expenditure ranging from around 14% to 50% of their revenues. Some of the...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 3 days agoThe company usually earns collaboration revenues from agreements with several big pharma/biotech...
BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
FOX21 Colorado Springs· 5 days agoBio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky ...
